<DOC>
	<DOCNO>NCT01221506</DOCNO>
	<brief_summary>All patient participate study receive pazopanib . Pazopanib oral drug ( pill ) approve U.S. Food Drug Administration ( FDA ) treatment advanced kidney cancer . In study , investigator plan learn way drug work use special scan ( MRIs Ultrasounds ) help evaluate drug work disease . Approximately 20 people advanced kidney cancer enrol study .</brief_summary>
	<brief_title>Pazopanib/DCE-MRIs Renal Cell Carcinoma ( RCC )</brief_title>
	<detailed_description>Overall objective PRIMARY : - Assessment early change DCE-MRI ultrasound measure tumor perfusion set pazopanib therapy patient metastatic clear cell renal cell carcinoma SECONDARY : - Correlation baseline DCE-MRI ultrasound parameter clinical outcome - Correlation early ( 48 +/- 24 hr treatment ) change DCE-MRI ultrasound parameter clinical outcome - Correlation baseline ( change ) DCE-MRI ultrasound parameter VHL status tumor histocytometric analysis endothelial cell activation archival nephrectomy specimens - Provide insight respective predictive value DCE-MRI US pazopanib treatment</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>18 year age old Diagnosis unresectable and/or metastatic clear cell renal cell carcinoma . 10 patient enrol prior antiangiogenic therapy ; 10 patient enrol one prior antiangiogenic therapy Prior radiation therapy symptomatic site metastatic disease allow patient must discontinued/completed radiation therapy least 2 week prior enter study , recover adverse event due treatment . ECOG performance status 0 , 1 2 . Patients must measureable disease RECIST 1.1 Archived tumor block must provide subject correlative analysis treatment pazopanib Patient must normal baseline laboratory value Patients must receive investigational agent onstudy . Patients must take cytochrome P450 enzyme induce antiepileptic drug ( phenytoin , carbamazepine phenobarbital ) , rifampin St.Johns wort . Females childbearing potential eligible enter participate study negative pregnancy test agree use medically accept contraception throughout study Female subject pregnant brestfeeding Patients active prior malignancy . Note : Subjects another malignancy diseasefree 3 year , subject history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma eligible . Patients history clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except individual previouslytreated CNS metastasis , asymptomatic , requirement steroid antiseizure medication 6 month prior first dose study drug . Screening CNS image study ( compute tomography [ CT ] magnetic resonance image [ MRI ] ) require clinically indicated subject history CNS metastasis . Patients clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding Patients clinically significant gastrointestinal abnormality may affect absorption investigational product Patients presence uncontrolled infection . Patient correct QT interval ( QTc ) great 480 msec use Bazetts formula Patients history one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting ; Myocardial infarction ; Unstable angina ; Coronary artery bypass graft surgery ; Symptomatic peripheral vascular disease ; Class III IV congestive heart failure , define New York Heart Association ( NYHA ) [ See Section YYY Appendix Y description Patient poorly control hypertension [ define systolic blood pressure ( SBP ) great equal 140 mmHg diastolic blood pressure ( DBP ) great equal 90mmHg ] . Patients history cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Note : Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible Patients prior major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer ( procedure catheter placement consider major ) . Patients evidence active bleeding bleed diathesis . Patients know endobronchial lesion and/or lesion infiltrate major pulmonary vessel Patients hemoptysis within 6 week first dose study drug . Patients serious and/or unstable preexist medical , psychiatric , condition could interfere subject safety , provision inform consent , compliance study procedure . Patients unable unwilling discontinue use prohibit medication list Section4.3 least 14 day five halflives drug ( whichever longer ) prior first dose study drug duration study . Treatment follow anticancer therapy : radiation therapy , surgery tumor embolization within 14 day prior first dose pazopanib ; OR chemotherapy , immunotherapy , biologic therapy , investigational therapy hormonal therapy within 14 day prior first dose pazopanib . Treatment prior sorafenib , sunitinib , temsirolimus everolimus allow must discontinue least 5 day prior begin pazopanib . Patient ongoing toxicity prior anticancer therapy great Grade 1 and/or progress severity , except alopecia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>unresectable</keyword>
	<keyword>metastatic</keyword>
	<keyword>clear cell renal carcinoma</keyword>
</DOC>